MariMed Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

MEZZANINE EQUITY (Details Narrative)

MEZZANINE EQUITY (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended	12 Months Ended
MEZZANINE EQUITY (Details Narrative) - USD ($)	Mar. 31, 2021	Feb. 29, 2020	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Payments of Stock Issuance Costs				$ 386,983
Proceeds from Issuance or Sale of Equity	$ 23,000,000.0
Payments for Construction in Process	$ 7,800,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				26,351,571	16,917,168
Maximum [Member] \| Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.50	$ 5.50
Minimum [Member] \| Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.11	$ 0.11
Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.087
Fair Value Adjustment of Warrants	$ 9,500,000
Payments of Stock Issuance Costs	$ 387,000
Hadron Healthcare Master Fund [Member] \| Maximum [Member] \| Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,540,540
3M Note [Member]
Repayments of Debt and Lease Obligation			$ 15,200,000
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Warrants term	4 years
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price Less Than Or Equal To $0.50 Per Share [Member]
Series B preferred stock conversion price, description		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price Greater Than $0.50 Per Share [Member]
Series B preferred stock conversion price, description		If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the sixty-day VWAP per share and pay cash to the Series B Holders at the difference between $3.00 per share and the sixty-day VWAP per share.
Series B Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Two Institutional Shareholders [Member]
Stock Issued During Period Shares Exchanged		4,908,333
Shares Issued, Price Per Share		$ 3.00
Series B Holders [Member]
Shares Issued, Price Per Share		3.00
Preferred Stock, Convertible, Conversion Price		$ 3.00
Series C Convertible Preferred Stock [Member] \| Minimum [Member]
Outstanding percentage.	50.00%
Series C Convertible Preferred Stock [Member] \| Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Stock Issued During Period, Shares, New Issues	6,216,216
Series C Convertible Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member]
Shares Issued, Price Per Share	$ 3.70
Stock Issued During Period, Value, New Issues	$ 23,000,000.0
Series C Convertible Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Maximum [Member]
Stock Issued During Period, Shares, New Issues	46,000,000.0